建科院(300675.SZ):上半年業績扭虧為盈 預盈280萬元-420萬元
格隆匯 7 月 16日丨建科院(300675.SZ)公佈,預計上半年實現歸屬於上市公司股東的淨利潤歸屬於上市公司股東的淨利潤280萬元-420萬元,上年同期虧損:1,237.53萬元,實現扭虧為盈。
報告期內,公司業績同比實現扭虧。主要原因如下:1、面對新冠疫情,公司採取多項措施,較早組織復工復產,並採取有效措施保證經營生產活動正常組織開展。2、落實以綠色城市全過程技術服務為支撐的“城市客户”戰略,捕捉深圳、雄安等區域市場復甦發展機遇,公司整體經營情況同比實現一定提升。3、在防疫成本增加的情況下,公司全面優化經營成本費用預算,提高內部運營效率,有效節約上半年成本費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.